Loading
Relcobatinib is an experimental oral small-molecule kinase inhibitor from Enliven Therapeutics, in phase 1 trials for chronic myeloid leukaemia.
Relcobatinib (ELVN-001) is an oral small-molecule kinase inhibitor (ATP-competitive) from Enliven Therapeutics. A highly selective ATP-competitive BCR::ABL1 inhibitor that binds a P-loop "folded-in" active conformation of ABL1; designed to avoid off-target activity and to cover mutations that cause resistance to allosteric inhibitors such as asciminib. Its furthest stage is phase 1, for chronic myeloid leukaemia. ClinicalTrials.gov registers it in 3 studies linked below. Phase 1 ENABLE recruiting (NCT05304377, NCT06787144); phase 3 ENABLE-2 versus investigator-selected TKI (NCT07905183) registered, not yet recruiting. Whether it works in people has not been established unless a trial below reports it.
A highly selective ATP-competitive BCR::ABL1 inhibitor that binds a P-loop "folded-in" active conformation of ABL1; designed to avoid off-target activity and to cover mutations that cause resistance to allosteric inhibitors such as asciminib. Connects to BCR::ABL1 (Philadelphia chromosome).
1.Relcobatinib slips into a pocket on BCR::ABL1 (Philadelphia chromosome).
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Relcobatinib" OR ABSTRACT:"Relcobatinib" OR TITLE:"ELVN-001" OR ABSTRACT:"ELVN-001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Relcobatinib, not a curated reading list.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/